ASPICULAMYCIN, A NEW CYTOSINE NUCLEOSIDE ANTIBIOTIC IV. ANTIMYCOPLASMA ACTIVITY OF ASPICULAMYCIN IN VITRO AND IN VIVO

Abstract

IV. ANTIMYCOPLASMA ACTIVITY OF ASPICULAMYCIN in vitro AND IN VIVOkn-subtitle=en-abstract=Aspiculamycin, a new cytosine nucleoside antibiotic produced by Streptomyces toyocaensis var. aspiculamyceticus, showed strong activity against various strains of Mycoplasma in vitro and in vivo. The minimal inhibitory concentration of the antibiotic ranged between 50 to 0.05mcg/ml by agar dilution, broth dilution or microtiter method. No influences of inoculum size and pH of the medium on the activity were observed. A number of strains of Mycoplasma gallisepticum showing resistance to macrolide antibiotics were all susceptible to the antibiotic. L-Forms derived from Staphylococcus aureus and Proteus vulgaris were insensitive to the antibiotic. After administration of 0.04% (w/w) of aspiculamycin in the basal diet for seven days, the lung and trachea of mice infected intranasally with Mycoplasma pulmonis were free of pathogen. In the experimental mice arthritis induced with M. pulmonis, the Mycoplasma could not be detected in joints of the mice after treatment with aspiculamycin at a dose of 0.05% (w/w) in the diet for ten days.